|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROREGULATION AND MOTILITY
1Groupe d'Etude du Stress et des Interactions Neuro-Digestives, Equipe dAccueil 3744, Department of Gastroenterology, Centre Hospitalier Universitaire de Grenoble, Grenoble; and 2Department of Radiobiology and Radiopathology, Centre de Recherches du Service de Santé des Armées, La Tronche, France
Submitted 9 July 2004 ; accepted in final form 4 January 2005
Corticotropin-releasing factor (CRF)-like peptides mediate their effects via two receptor subtypes, CRF1 and CRF2; these receptors have functional implication in the motility of the stomach and colon in rats. We evaluated expression and functions of CRF1 and CRF2 receptors in the rat small intestine (i.e., duodenum and ileum). CRF12-like immunoreactivity (CRF12-LI) was localized in fibers and neurons of the myenteric and submucosal ganglia. CRF12-LI was found in nerve fibers of the longitudinal and circular muscle layers, in the mucosa, and in mucosal cells. Quantitative RT-PCR showed a stronger expression of CRF2 than CRF1 in the ileum, whereas CRF1 expression was higher than CRF2 expression in the duodenum. Functional studies showed that CRF-like peptides increased duodenal phasic contractions and reduced ileal contractions. CRF1 antagonists (CP-154,526 and SSR125543Q) blocked CRF-like peptide-induced activation of duodenal motility but did not block CRF-like peptide-induced inhibition of ileal motility. In contrast, a CRF2 inhibitor (astressin2-B) blocked the effects of CRF-like peptides on ileal muscle contractions but did not influence CRF-like peptide-induced activation of duodenal motility. These results demonstrate the presence of CRF12 in the intestine and demonstrate that, in vitro, CRF-like peptides stimulate the contractile activity of the duodenum through CRF1 receptor while inhibiting phasic contractions of the ileum through CRF2 receptor. These results strongly suggest that CRF-like peptides play a major role in the regulatory mechanisms that underlie the neural control of small intestinal motility through CRF receptors.
astressin2-B; corticotropin-releasing factor receptors; urocortin
This article has been cited by other articles:
![]() |
T. Kimura, T. Amano, H. Uehara, H. Ariga, T. Ishida, A. Torii, H. Tajiri, K. Matsueda, and S. Yamato Urocortin I is present in the enteric nervous system and exerts an excitatory effect via cholinergic and serotonergic pathways in the rat colon Am J Physiol Gastrointest Liver Physiol, October 1, 2007; 293(4): G903 - G910. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. LaBerge, S. E. Malley, K. Zvarova, and M. A. Vizzard Expression of corticotropin-releasing factor and CRF receptors in micturition pathways after cyclophosphamide-induced cystitis Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2006; 291(3): R692 - R703. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bisschops, P. Vanden Berghe, G. Sarnelli, J. Janssens, and J. Tack CRF-induced calcium signaling in guinea pig small intestine myenteric neurons involves CRF-1 receptors and activation of voltage-sensitive calcium channels Am J Physiol Gastrointest Liver Physiol, June 1, 2006; 290(6): G1252 - G1260. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |